BASG statement
messages in brief
|
07/10/2013
Last June, the European Medicines Agency (EMA) published a draft policy on the publication of raw (patient) data from clinical trials.
This publication (was followed by a public comment period.BASG/AGES Medical Market Surveillance representatives, together with the Business Unit Manager, have drafted a statement from the perspective of the Austrian authority.
Queries:
BASG/AGES Medical Market Surveillance
E-mail: c linicaltrials@ages.at
Further inquiry note
Page last modified:
11/07/2022